Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Thermo Fisher to drop $1.7B on gene therapy maker Brammer Bio

March 25, 2019 By Nancy Crotti

Thermo Fisher (NYSE:TMO) said today that it will acquire gene and cell therapy manufacturer Brammer Bio for $1.7 billion in cash.

Brammer Bio is a viral vector contract developer and manufacturer of gene therapies and gene-modified cell therapies for biopharma customers. The Cambridge, Mass.-based business has nearly 600 employees at primary locations in Massachusetts and Alachua, Fla.

Brammer Bio is on track to deliver $250 million in revenue in 2019 and expects to continue to exceed the projected market growth rate of 25% over the mid-term, according to a prepared statement. Thermo Fisher (Waltham, Mass.) said it expects the business to be accretive to adjusted earnings per share by $0.10 in the first full year of ownership.

“Brammer Bio will be an exciting addition to our pharma services business and will further strengthen Thermo Fisher’s leadership in serving pharma and biotech customers,” said Thermo Fisher president & CEO Marc Casper. “Gene therapy is an area of increasing focus for our customers and is fast-evolving, given its potential to treat a range of genetic disorders.”

“Brammer Bio has executed more than 100 projects to supply first-in-human gene therapy clinical trials and establish commercial-ready processes, and we’re excited to join Thermo Fisher to take our business to the next level,” added Brammer Bio president & CEO Mark Bamforth and chief scientific officer Dr. Richard Snyder. “Our teams share a commitment to helping our customers succeed in delivering cutting-edge therapies to patients in need.”

Thermo Fisher said it expects the transaction to be completed by the end of the second quarter of 2019. Brammer Bio will become part of Thermo Fisher’s pharma services business within its laboratory products and services segment.

Last October, Thermo Fisher acquired Becton Dickinson’s Advanced Bioprocessing business for $477 million. Thermo Fisher’s share price was up $3.17 or 1.2% to $267.09 on today’s news.

 

Related Articles Read More >

cybersecurity
Moody’s warns of cybersecurity, antitrust and supplier risks for medical device companies
Integer Holdings
Integer buys Aran Biomedical for $131.1 million
BD Diabetes Spinoff Embecta
How Embecta is ‘uniquely positioned’ in diabetes space following spinoff from BD
The CartiHeal Agili-C implant for treating cartilage lesions
Bioventus plans to buy CartiHeal for at least $315M to launch knee implant

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech